The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS). However, most of what scientists know about the impact of ...
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs). Patients with myelodysplastic ...
Myelodysplastic syndrome (MDS) is clonal disorder characterized by ineffective hematopoiesis and a tendency to evolve into acute myeloid leukemia (AML). Genetic studies have enabled the identification ...
Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window What we did is ...
Risk scoring methods continue to evolve with increased understanding of the factors that affect specific patient group outcomes in MDS. Diagnosis of MDS is currently based on morphology, but can be ...
A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer Age and exposure to ...
Clonal hematopoiesis is the expansion of a genetically related population of hematopoietic stem and progenitor cells that disproportionately contribute to blood-cell production. 1 Clonal hematopoiesis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback